Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive is a phase 2, interventional study registered as NCT07337551 by Guiying Wang, with a registry enrolment figure of 20 participants, started 2026-02-01 and due to reach its primary completion in 2028-02-01. Interventions recorded: Gossypol acetate Combined with Bevacizumab and FOLFIRI. Conditions listed: Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment. Primary outcome: Primary Endpoint. Colorectal eligibility wording from the registry: "Histopathologically or cytologically confirmed adenocarcinoma of the colon or rectum". No results are recorded here; the registry entry is the source.